Revenue And Profit GrowthSustained revenue growth and a 27% net margin show consistent demand and improving operational efficiency. Durable profitability supports reinvestment in capacity and quality, strengthens customer relationships, and provides a stable earnings base to fund future growth initiatives.

Strong Balance Sheet & Reduced LeverageA markedly stronger equity base and reduced debt materially lower financial risk and interest burden. This durable capital structure improves resilience to demand shocks, enables disciplined capex or strategic M&A, and increases flexibility to support long-term business investments.

Improving Cash GenerationRecovery to positive free cash flow and robust operating cash conversion enhance financial flexibility. Over the medium term this enables funding for working capital, targeted capex, and deleveraging without reliance on external financing, strengthening sustainable operations.

Bears Say

Free Cash Flow VolatilityHistorical FCF swings indicate uneven cash available for reinvestment and returns. Such volatility complicates long-term planning for capex and dividends, increases refinancing or liquidity risk in downturns, and means recent FCF improvement may not be fully structural yet.

Moderate Earnings GrowthMid-single-digit EPS growth and sub-10% revenue growth are modest for a specialty pharma/API business. Slower organic expansion limits scale economies and R&D funding, requiring either margin gains or new product wins to achieve materially faster long-term value creation.

Concentration In API ManufacturingHeavy reliance on bulk API production exposes the company to regulatory scrutiny, customer contract cycles, and pricing pressure in commodity-like segments. This structural concentration increases sensitivity to regulatory changes and demand shifts across geographies, pressuring long-term stability.

Supriya Lifescience Limited News

Supriya Lifescience Publishes Postal Ballot Notice in Newspapers

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has provided an update. Supriya Lifescience Limited notified the stock exchanges that...

4d ago

Supriya Lifescience Closes Trading Window Ahead of Q3 FY26 Results

An announcement from Supriya Lifescience Limited ( ($IN:SUPRIYA) ) is now available. Supriya Lifescience Limited has announced the...

3M ago

Supriya Lifescience Schedules Earnings Call to Discuss Financial Performance

Supriya Lifescience Limited ( ($IN:SUPRIYA) ) has issued an announcement. Supriya Lifescience Limited has announced an upcoming earnings...

4M ago

Supriya Lifescience Discloses Key Managerial Personnel Details

The latest announcement is out from Supriya Lifescience Limited ( ($IN:SUPRIYA) ). Supriya Lifescience Limited has announced the...

1y ago

SUPRIYA FAQ

What was Supriya Lifescience Limited’s price range in the past 12 months?

Supriya Lifescience Limited lowest stock price was ₹573.45 and its highest was ₹841.70 in the past 12 months.

What is Supriya Lifescience Limited’s market cap?

Supriya Lifescience Limited’s market cap is ₹46.48B.

When is Supriya Lifescience Limited’s upcoming earnings report date?

Supriya Lifescience Limited’s upcoming earnings report date is Jun 02, 2026 which is in 78 days.

How were Supriya Lifescience Limited’s earnings last quarter?

Supriya Lifescience Limited released its earnings results on Feb 09, 2026. The company reported ₹6.2 earnings per share for the quarter, beating the consensus estimate of N/A by ₹6.2.

Is Supriya Lifescience Limited overvalued?

According to Wall Street analysts Supriya Lifescience Limited’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Supriya Lifescience Limited pay dividends?

Supriya Lifescience Limited pays a Annually dividend of ₹1 which represents an annual dividend yield of 0.13%. See more information on Supriya Lifescience Limited dividends here

What is Supriya Lifescience Limited’s EPS estimate?

Supriya Lifescience Limited’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Supriya Lifescience Limited have?

Supriya Lifescience Limited has 80,482,800 shares outstanding.

What happened to Supriya Lifescience Limited’s price movement after its last earnings report?

Supriya Lifescience Limited reported an EPS of ₹6.2 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 2.803%.

Which hedge fund is a major shareholder of Supriya Lifescience Limited?

Currently, no hedge funds are holding shares in IN:SUPRIYA

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Supriya Lifescience Limited

Supriya Lifescience Ltd., a bulk drugs company, engages in the research and development, manufacture, and sale of active pharmaceutical ingredients worldwide. It offers active pharmaceutical ingredients, such as anti-histamine, anti-allergic, anti-asthmatic, decongestant, analgesic/anti-pyretic/anesthetic, smoking cessation, antihypertensive, and anti-malarial products, as well as vitamins, feed additives, xanthine derivatives and beverages, and phytochemicals. The company was founded in 1987 and is headquartered in Mumbai, India.